Peroxisome proliferator-activated receptor-α modulates the anti-inflammatory effect of glucocorticoids in a model of inflammatory bowel disease in mice

Shock

Volumn 31, Issue 3, 2009, Pages 308-316

  Riccardi, Luisa ^a   Mazzon, Emanuela ^b   Bruscoli, Stefano ^a   Esposito, Emanuela ^b,c   Crisafulli, Concetta ^d   Paola, Rosanna Di ^b   Caminiti, Rocco ^e   Riccardi, Carlo ^a   Cuzzocrea, Salvatore ^b,d,e  

^a UNIVERSITY OF PERUGIA   (Italy)

^b IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d Departments of Clinical and Experimental Medicine and Pharmacology   (Italy)

^e UNIVERSITY OF MESSINA   (Italy)

Author keywords

Bowel disease; Cytokines; Dexamethasone; Glucocorticoids; Ppar

Indexed keywords

CYCLOOXYGENASE 2; CYTOKINE; DEXAMETHASONE; FAS LIGAND; I KAPPA B; I KAPPA B ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN BAX; PROTEIN BCL 2; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; AUTACOID; BENZENESULFONIC ACID DERIVATIVE; DINITROBENZENESULFONIC ACID; GLUCOCORTICOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL MIGRATION; COLON INJURY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; ENTERITIS; KNOCKOUT MOUSE; MOUSE; NONHUMAN; OXIDATIVE STRESS; WILD TYPE; ANIMAL; CELL MOTION; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG POTENTIATION; GENETICS; METABOLISM; MOUSE MUTANT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; BENZENESULFONATES; CELL MOVEMENT; CYTOKINES; DEXAMETHASONE; GLUCOCORTICOIDS; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; MICE; MICE, KNOCKOUT; OXIDATIVE STRESS; PPAR ALPHA;

EID: 62449207118     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e31818339e7     Document Type: Article

References (33)

1. Cuzzocrea S: Emerging biotherapies for inflammatory bowel disease. Expert Opin Emerg Drugs 8:339-347, 2003.
2. Matsumoto S, Okabe Y, Setoyama H, Takayama K, Ohtsuka J, Funahashi H, Imaoka A, Okada Y, Umesaki Y: Inflammatory bowel disease-like enteritis and cecitis in a senescence accelerated mouse P1/Yit strain. Gut 43( 1):71-78, 1998.
3. Blumberg RS, Saubermann LJ, Strober W: Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol 11(6):648-656, 1999.
4. Mazzon E, Puzzolo D, Caputi AP, Cuzzocrea S: Role of IL-10 in hepatocyte tight junction alteration in mouse model of experimental colitis. Mol Med 8(7):353-366, 2002.
5. Rhen T, Cidlowski JA: Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 353(16): 1711-1723, 2005.
6. Bruscoli S, Di Virgilio R, Donato V, Velardi E, Baldoni M, Marchetti C, Migliorati G, Riccardi C: Genomic and non-genomic effects of different glucocorticoids on mouse thymocyte apoptosis. Eur J Pharmacol 529(1-3): 63-70, 2006.
7. Neve BP, Corseaux D, Chinetti G, Zawadzki C, Fruchart JC, Duriez P, Staels B, Jude B: PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 103(2):207-212, 2001.
8. Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, Desvergne B: Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 142(10):4195-4202, 2001.
9. Mansen A, Guardiola-Diaz H, Rafter J, Branting C, Gustafsson JA: Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochem Biophys Res Commun 222(3):844-851, 1996.
10. Bernal-Mizrachi C, Xiaozhong L, Yin L, Knutsen RH, Howard MJ, Arends JJ, Desantis P, Coleman T, Semenkovich CF: An afferent vagal nerve pathway links hepatic PPARalpha activation to glucocorticoid-induced insulin resistance and hypertension. Cell Metab 5(2):91-102, 2007.
11. Okamoto H, Iwamoto T, Kotake S, Momohara S, Yamanaka H, Kamatani N: Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator- activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis. Clin Exp Rheumatol 23(3):323-330, 2005.
12. Cuzzocrea S, Mazzon E, Di Paola R, Peli A, Bonato A, Britti D, Genovese T, Muià C, Crisafulli C, Caputi AP: The role of the peroxisome proliferator- activated receptor-alpha (PPAR-alpha) in the regulation of acute inflammation. J Leukoc Biol 79(5):999-1010, 2006.
13. Cuzzocrea S, Bruscoli S, Mazzon E, Crisafulli C, Donato V, Di Paola R, Velardi E, Esposito E, Nocentini G, Riccardi C: Peroxisome proliferator- activated receptor-alpha contributes to the anti-inflammatory activity of glucocorticoids. Mol Pharmacol 73(2):323-337, 2008.
14. Sturiale S, Barbara G, Qiu B, Figini M, Geppetti P, Gerard N, Grady EF, Bunnett NW, Collins SM: Neutral endopeptidase (EC 3.4.24.11) terminates colitis by degrading substance P. Proc Natl Acad Sci USA 96(20): 11653-11658, 1999.
15. Mullane KM, Kraemer R, Smith B: Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J Pharmacol Methods 14(3): 157-167, 1985.
16. Diaz-Granados N, Howe K, Lu J, McKay DM: Dextran sulfate sodium- induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity. Am J Pathol 156(6): 2169-2177, 2000.
17. Di Marco B, Massetti M, Bruscoli S, Macchiarulo A, Di Virgilio R, Velardi E, Donato V, Migliorati G, Riccardi C: Glucocorticoid-induced leucine zipper (GILZ)/NF-kappaB interaction: role of GILZ homo-dimerization and C-terminal domain. Nucleic Acids Res 35(2):517-528, 2007.
18. Rachmilewitz D, Stamler JS, Karmeli F, Mullins ME, Singel DJ, Loscalzo J, Xavier RJ, Podolsky DK: Peroxynitrite-induced rat colitis-a new model of colonic inflammation. Gastroenterology 105(6):1681-1688, 1993.
19. Ischiropoulos H, Zhu L, Beckman JS: Peroxynitrite formation from macrophage-derived nitric oxide. Arch Biochem Biophys 298(2):446-451, 1992.
20. Schreck R, Rieber P, Baeuerle PA: Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J 10(8):2247-2258, 1991.
21. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M: Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270(5234):286-290, 1995.
22. Ayroldi E, Zollo O, Bastianelli A, Marchetti C, Agostini M, Di Virgilio R, Riccardi C: GILZ mediates the antiproliferative activity of glucocorticoids by negative regulation of Ras signaling. J Clin Invest 117(6): 1605-1615, 2007.
23. Vlahos R, Stewart AG: Interleukin-1 alpha and tumour necrosis factor-alpha modulate airway smooth muscle DNA synthesis by induction of cyclo-oxygenase-2: inhibition by dexamethasone and fluticasone propionate. Br J Pharmacol 126(6):1315-1324, 1999.
24. Sharma K, Wang RX, Zhang LY, Yin DL, Luo XY, Solomon JC, Jiang RF, Markos K, Davidson W, Scott DW, et al.: Death the Fas way: regulation and pathophysiology of CD95 and its ligand. Pharmacol Ther 88(3):333-347, 2000.
25. Sayani FA, Keenan CM, Van Sickle MD, Amundson KR, Parr EJ, Mathison RD, MacNaughton WK, Braun JE, Sharkey KA: The expression and role of Fas ligand in intestinal inflammation. Neurogastroenterol Motil 16(l):61-74, 2004.
26. Bauer MK, Vogt M, Los M, Siegel J, Wesselborg S, Schulze-Osthoff K: Role of reactive oxygen intermediates in activation-induced CD95 (APO-l/Fas) ligand expression. J Biol Chem 273(14):8048-8055, 1998.
27. Leist M, Fava E, Montecucco C, Nicotera P: Peroxynitrite and nitric oxide donors induce neuronal apoptosis by eliciting autocrine excitotoxicity. Eur J Neurosci 9(7): 1488-1498, 1997.
28. Iwamoto M, Koji T, Makiyama K, Kobayashi N, Nakane PK: Apoptosis of crypt epithelial cells in ulcerative colitis. J Pathol 180(2):152-159, 1996.
29. Bu P, Keshavarzian A, Stone DD, Liu J, Le PT, Fisher S, Qiao L: Apoptosis: one of the mechanisms that maintains unresponsiveness of the intestinal mucosal immune system. J Immunol 166(10):6399-6403, 2001.
30. Zingarelli B, Szabo C, Salzman AL: Blockade of Poly(ADP-ribose) synthetase inhibits neutrophil recruitment, oxidant generation, and mucosal injury in murine colitis. Gastroenterology 116(2):335-345, 1999.
31. Lovett-Racke AE, Hussain RZ, Northrop S, Choy J, Rocchini A, Matures L, Chavis JA, Diab A, Drew PD, Racke MK: Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J Immunol 172(9): 5790-5798, 2004.
32. Sands BE: Inflammatory bowel disease: past, present, and future. J Gastroenterol 42(l):16-25, 2007.
33. Meduri GU, Muthiah MP, Carratu P, Eltorky M, Chrousos GP: Nuclear factor- kappaB- and glucocorticoid receptor alpha-mediated mechanisms in the regulation of systemic and pulmonary inflammation during sepsis and acute respiratory distress syndrome. Evidence for inflammation-induced target tissue resistance to glucocorticoids. Neuroimmunomodulation 12:(6)321-338, 2005.